Retrospective Study of Sorafenib Efficacy and Safety in Chinese Patients with Recurrence Rate of Post-Hepatic Carcinectomy

Jul 18, 2019 | Cancer, Hepatocellular Carcinoma, Liver Cancer, Oncology

medical book

Chinese investigators conducted a retrospective analysis of sorafenib efficacy and safety in Chinese patients with a high recurrence rate of post-hepatic carcinectomy. The research team found that sorafenib may be considered as a feasible option in the treatment of HCC recurrence.

The Study

Currently, the Chinese investigative team declares there is no guideline recommendation for preventing hepatocellular carcinoma (HCC) recurrence after hepatic resection. Moreover, an unmet need exists on the effectiveness of sorafenib therapy in recurrent HCC.

Consequently, the Chinese team sought to assess the efficacy and safety of sorafenib in Chinese HCC patients with a high risk of recurrence.

The team collected data retrospectively from 15 Chinese research centers by chart reviews of patients with moderate-advanced HCC who received hepatic carcinectomy. The primary endpoint was recurrence-free survival rate at 1 year in patients with high recurrence risk. Secondary endpoints included 1-year survival rate, time to recurrence and safety assessment as reported in Dovepress.

The Results

A total of 209 high-risk patients (sorafenib, n=98; control, n-111) who underwent carcinectomy were analyzed. There was no significant difference in the proportion of patients with recurrence-free survival at 1 year between the sorafenib and control (70.43% vs. 68.90%: χ2=0.007, P=0.934). 

One-year survival rate was significantly higher with sorafenib that observed with control (95.5% vs. 83.5% %; χ2=7.441, P=0.006). Time to recurrence between sorafenib and control groups was similar. Incidence of all the adverse events (AEs) was similar in both the groups and transaminase elevation was most common in both groups (20.37% vs 24.79%). Thrombocytopenia incidence was significantly lower with the sorafenib group than with control (1.85% vs 9.40%; P=0.015). Sorafenib may be considered as a feasible option in the treatment of HCC

What is Sorafenib

Made by Bayer, it is a cancer treatment known by its brand name Nexavar. It is a targeted cancer drug and possible treatment for a type of liver cancer (hepatocellular carcinoma).

Research Centers

  • Department of Hepatobiliary Surgery, Xijing Hospital, Shaanxi, China
  • Department of Hepatobiliary Surgery, Anhui Provincial Hospital, Hefei, China
  • Department of Hepatobiliary Surgery, Xiangya Hospital, Changsha, China
  • Department of Hepatobiliary Surgery, West China Hospital, Chengdu, China
  • Department of Hepatobiliary Surgery, Cancer Hospital of Xinjiang, Urumqi, China
  • Department of Hepatobiliary Surgery, Southwest Hospital, Chongqing, China
  • Department of Hepatobiliary Surgery, Cancer Hospital of Henan, Zhengzhou, China
  • Department of Hepatobiliary Surgery, Cancer Hospital of Guangxi Medical University, Nanning, China
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
  • Department of Hepatobiliary Surgery, The First Affiliated Hospital of Kunming Medical University, Kunming, China
  • Department of Hepatobiliary Surgery, Cancer Hospital of Jiangxi, Nanchang, China
  • Department of Hepatobiliary Surgery, Wuhan Union Hospital, Wuhan, China
  • Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Xiangya, Changsha, China
  • Department of Hepatopancreatobiliary Surgery, Cancer Hospital of Sichuan, Chengdu, China
  • Department of Hepatobiliary Surgery, Wuhan Tongji Hospital, Wuhan, China

0 Comments

Pin It on Pinterest